Profile

Specific Biologics is developing Dualase®, an industry-leading genome editing platform with best-in-class accurate editing efficiency, undetectable off-target effects, and plug-and-play programmability with broad therapeutic potential as in vivo medicines with proof-of-concept in preclinical animal models. Dualase®’s two-site mechanism enables seamless removal, repair and insertion of small or large DNA sequences. Its differentiated pipeline of developments candidates addresses mutations that other genome editors cannot, with an initial focus on repeat expansion disorders in neurodegenerative disease.

Specific Biologics logo

Website

specificbiologics.com

Contact


Event details

Date: November 3 - 5, 2025

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

22 in total